Transferring an HPLC Method for Related Substances from Different LC Platforms to an ACQUITY Arc System

Importance of the Topic

Transferring analytical methods reliably between liquid chromatography platforms is critical in pharmaceutical quality control. A robust transfer ensures consistent results across different instruments and laboratories without time-consuming revalidation. Efficient method transfer supports regulatory compliance, reduces development costs, and accelerates project timelines.

Objectives and Study Overview

This study demonstrates the transfer of an HPLC method for related substances of metoclopramide hydrochloride from three common LC systems (Agilent 1100, Agilent 1260, Alliance HPLC) to a Waters ACQUITY Arc System. It also evaluates method scaling to columns with smaller particle sizes to improve throughput and reduce solvent consumption.

Methodology and Instrumentation

Sample Preparation:

• Stock solutions of metoclopramide and nine related impurities prepared at 1.0 mg/mL in methanol; API diluted to 0.5 mg/mL and spiked at 1.0% impurity level.
• System suitability standard prepared at 15 µg/mL per analyte in 50:50 methanol/water.

Chromatographic Conditions:

• Original column: XSelect CSH C18, 4.6 × 150 mm, 5 µm; gradient elution (95% to 40% A over 15 min).
• Scaled columns: 3.0 × 100 mm (3.5 µm) and 3.0 × 75 mm (2.5 µm); flow rate and gradient times geometrically scaled.
• Mobile phases: 0.1% formic acid in water (A) and methanol (B).

Instrumentation:

• Waters ACQUITY Arc System with Arc Multi-flow Path™ technology to match dwell volumes.
• ACQUITY QDa® Detector for mass-based peak confirmation (ESI+, 100–440 m/z).
• Empower® 3 CDS for data acquisition and analysis.

Main Results and Discussion

Method Transfer:

• Selecting fluidic path 1 on the Arc System reproduced gradient dwell volumes of Agilent and Alliance systems without altering the gradient program.
• Chromatograms showed equivalent retention times, peak shapes, and resolution across all platforms.
• System suitability parameters (USP resolution ≥ 3.0 for API/Imp. A; tailing ≤ 1.5) were met or exceeded on the Arc System, with RSDs of retention time and area well below 2.0%.

Mass Detection:

• ACQUITY QDa provided rapid confirmation of all nine impurities and API by monoisotopic masses, enhancing confidence in peak assignments.

Method Scaling:

• 3.5 µm column reduced run time by 33% and solvent use by 72% versus the 5 µm method.
• 2.5 µm column achieved a 50% shorter analysis time and 79% solvent reduction.
• All scaled methods maintained chromatographic integrity and system suitability criteria.

Benefits and Practical Applications

The ACQUITY Arc System with Multi-flow Path™ technology simplifies method transfers across varied LC platforms, minimizing method redevelopment and revalidation. Coupled with the QDa detector, it provides streamlined impurity identification. Scaling to sub-3 µm columns further enhances lab throughput and reduces solvent costs, translating into higher productivity and sustainability.

Future Trends and Opportunities

Emerging opportunities include integration of automated method translation software, wider adoption of multi-flow path systems for complex gradient methods, and expansion of mass detection in routine QC workflows. Continued miniaturization and high-pressure capabilities will drive faster analyses and lower environmental impact.

Conclusion

The Waters ACQUITY Arc System effectively replicates and improves a metoclopramide related-substances HPLC method transferred from multiple LC platforms. Multi-flow path technology and QDa mass detection ensure accurate, compliant results. Scaling to smaller particle columns yields significant time and solvent savings while preserving method performance.

References

1. Jones MD, Alden P, Fountain KJ, Aubin A. Implementation of Methods Translation between Liquid Chromatography Instrumentation. Waters Corp. 2010: 720003721en.
2. USP Monograph, Metoclopramide Hydrochloride, USP38-NF33, United States Pharmacopeia Convention, August 2015.
3. USP General Chapter <621> Chromatography, USP38-NF33, United States Pharmacopeia Convention, August 2015.
4. Waters Corporation. ACQUITY Arc System website information; 2016.